Median OS was 8.6 months for figitumumab plus chemotherapy and 9.8 months for chemotherapy alone ( hazard ratio [ HR ] , 1.18 ; 95 % CI , 0.99 to 1.40 ; P = .06 ) ; median progression-free survival was 4.7 months ( 95 % CI , 4.2 to 5.4 ) and 4.6 months ( 95 % CI , 4.2 to 5.4 ) , respectively ( HR , 1.10 ; P = .27 ) ; the objective response rates were 33 % and 35 % , respectively .
